Characterization of a Standardized Glucagon Challenge Test as a Pharmacodynamic Tool in Pharmacological Research

Abstract

The aim of this study was to characterize a glucagon challenge test as a tool in diabetes research by assessing the inter- and intra-individual variability, and investigating the activity of the autonomic nervous system (ANS) during the challenge, as this might have an indirect impact on glucose homeostasis. The study was performed in 24 healthy volunteers separated in 2 groups. The first group of 12 volunteers underwent a 5-h glucagon challenge during a pancreatic clamp procedure with infusion of [6,6-²H₂]-glucose infusion in combination with heart rate variability measurements. In the second group, 12 other healthy volunteers underwent two 6-h glucagon challenges separated by 6 weeks, and fat biopsies were taken for analysis of glucagon receptor expression. Serum glucose rose rapidly after glucagon infusion, and reached a plateau at 90 min. The time profiles suggested rapid development of tolerance for glucagon-induced hyperglycemia. During the glucagon challenge intra- and inter-individual variabilities for hepatic glucose production, the rate of disappearance of glucose, and plasma glucose were approximately 10–15% for all variables. Hyperglucagonemia did not affect heart rate variability. Human adipose tissue had a low, but variable, expression of glucagon receptor mRNA. This standardized glucagon challenge test has a good reproducibility with only limited variability over 6 weeks. It is a robust tool to explore in detail the contribution of glucagon in normal and altered glucose homeostasis and can also be used to evaluate the effects of drugs antagonizing glucagon action in humans without confounding changes in ANS tone.

Key words

glucagon - diabetes mellitus type 2 - hepatic glucose production - autonomic nervous system

• References

• 1 Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053
• 2 Lebovitz H. Diabetes: assessing the pipeline. Atheroscler Suppl 2006; 7: 43-49
• 3 Rothman DL, Magnusson I, Katz LD, Shulman RG, Shulman GI. Quantitation of hepatic glycogenolysis and gluconeogenesis in fasting humans with ¹³C NMR. Science 1991; 254: 573-576
• 4 Sloop KW, Michael MD, Moyers JS. Glucagon as a target for the treatment of Type 2 diabetes. Expert Opin Ther Targets 2005; 9: 593-600
• 5 Svoboda M, Tastenoy M, Vertongen P, Robberecht P. Relative quantitative analysis of glucagon receptor mRNA in rat tissues. Mol Cell Endocrinol 1994; 105: 131-137
• 6 Edgerton DS, Cherrington AD. Glucagon as a critical factor in the pathology of diabetes. Diabetes 2011; 60: 377-380
• 7 Petersen KF, Sullivan JT. Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans. Diabetologia 2001; 44: 2018-2024
• 8 Rivera N, Everett-Grueter CA, Edgerton DS, Rodewald T, Neal DW, Nishimura E, Larsen MO, Jacobsen LO, Kristensen K, Brand CL, Cherrington AD. A novel glucagon receptor antagonist, NNC 25-0926, blunts hepatic glucose production in the conscious dog. J Pharmacol Exp Ther 2007; 321: 743-752
• 9 Sorensen H, Brand CL, Neschen S, Holst JJ, Fosgerau K, Nishimura E, Shulman GI. Immunoneutralization of endogenous glucagon reduces hepatic glucose output and improves long term glycemic control in diabetic ob/ob mice. Diabetes 2006; 55: 2843-2848
• 10 Lockton JA, Poucher SM. Single dose glucagon (0.5 mg IV bolus) administration in healthy human volunteers is a robust model for assessment of glycogenolysis: characterisation of the glucose excursion after glucagon challenge. J Pharmacol Toxicol Meth 2007; 55: 86-90
• 11 Farah A, Tuttle R. Studies on the pharmacology of glucagon. J Pharmacol Exp Ther 1960; 129: 49-55
• 12 White CM. A review of potential cardiovascular uses of intravenous glucagon administration. J Clin Pharmacol 1999; 39: 442-447
• 13 Hansen LH, Abrahamsen N, Nishimura E. Glucagon receptor mRNA distribution in rat tissues. Peptides 1995; 16: 1163-1166
• 14 Li QS, Liu X, van Doorn MBA, Kemme MJB, van Hoogdalen EJ, Cohen AF, Jones CR, Ouwens M, Burggraaf J, de Kam ML. Biopsy and RNA extraction procedures of muscle and adipose tissue for microarray gene-expression profiling. In: Biochips as pathways to drug discovery. Carmen A, Hardiman G. (eds.) Boca Raton, Florida: CRC; 2006: 109-122
• 15 Heart rate variability . Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J 1996; 17: 354-381
• 16 Reinauer H, Gries FA, Hubinger A, Knode O, Severing K, Susanto F. Determination of glucose turnover and glucose oxidation rates in man with stable isotope tracers. J Clin Chem Clin Biochem 1990; 28: 505-511
• 17 Liang Y, Osborne MC, Monia BP, Bhanot S, Gaarde WA, Reed C, She P, Jetton TL, Demarest KT. Demarest KT. Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. Diabetes 2004; 53: 410-417
• 18 Rosenblatt J, Wolfe RR. Calculation of substrate flux using stable isotopes. Am J Physiol 1988; 254: E526-E531
• 19 Chernish SM, Maglinte DD. Glucagon: common untoward reactions – review and recommendations. Radiology 1990; 177: 145-146
• 20 Matsuda M, DeFronzo RA, Glass L, Consoli A, Giordano M, Bressler P, Delprato S. Glucagon dose-response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals. Metabolism 2002; 51: 1111-1119
• 21 Magnusson I, Rothman DL, Gerard DP, Katz LD, Shulman GI. Contribution of hepatic glycogenolysis to glucose production in humans in response to a physiological increase in plasma glucagon concentration. Diabetes 1995; 44: 185-189
• 22 Ferrannini E, DeFronzo RA, Sherwin RS. Transient hepatic response to glucagon in man: role of insulin and hyperglycemia. Am J Physiol 1982; 242: E73-E81
• 23 Merlen C, Fabrega S, Desbuquois B, Unson CG, Authier F. Glucagon-mediated internalization of serine-phosphorylated glucagon receptor and Gsalpha in rat liver. FEBS Lett 2006; 580: 5697-5704
• 24 Cherrington AD. Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo. Diabetes 1999; 48: 1198-1214
• 25 Thorens B. Glucose sensing and the pathogenesis of obesity and type 2 diabetes. Int J Obes (Lond) 2008; 32 (Suppl. 06) S62-S71